A new opinion piece in STAT News highlights a critical gap in rare disease treatment access. The author details how their brother, an adult with Hunter syndrome, cannot obtain a recently approved breakthrough drug. This case underscores a systemic problem where clinical trials and drug approvals focus primarily on pediatric populations.
Rare disease research, policy discussions, and advocacy efforts frequently prioritize children, leaving adult patients behind. The article argues this creates an inequitable system where age becomes a barrier to life-altering therapies. It points to a broader pattern in which regulatory and development pathways fail to address the needs of aging rare disease populations.
The piece uses the specific example of avlayah, a drug for Hunter syndrome, to illustrate the issue. While the treatment has received approval, its access appears limited based on patient age. The author contends that such age-based restrictions in clinical trials and subsequent approvals are a form of discrimination.
This situation raises urgent questions about drug development incentives and post-approval access protocols. Pharmaceutical companies and regulators face pressure to demonstrate efficacy in younger patients, which can sideline older cohorts. The advocacy community is now being called to broaden its focus to include all age groups affected by rare conditions.
If unaddressed, this trend could erode trust in the regulatory process and leave a growing population of adult patients without hope. The article serves as a rallying cry for more inclusive research and reimbursement policies that span a patient's entire lifespan.